Walvax is engaged in research and development, manufacturing, and distribution of vaccines. The company focuses on producing safe and efficacious vaccines.

Walvax

Walvax | 799 followers on LinkedIn. Help everyone live a healthy life! | Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality vaccines.

Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.

Director Of Research Development at Walvax Biotechnology Co., Ltd.

Xin Tong

HR at Walvax, a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality…

Li Y.

Senior Specialist in Audit & Compliance at Walvax Biotech

Rick Zhang

Manager of Market Development and Management at Walvax Biotechnology Co., Ltd.

Huazhi Yang

🌿📊 Proud to announce exciting news in sustainable investing! In September 2024, MSCI upgraded Walvax Biotechnology's ESG rating to BBB, marking a significant milestone in our commitment to environmental, social, and governance practices. 👏 Key highlights from the report: Our Access to Health Care initiatives scored above the industry average, reflecting our dedication to improving global health outcomes. Product Safety & Quality also exceeded industry standards, underscoring our unwavering commitment to delivering safe, high-quality and efficacious vaccines to every corner of the world. This upgrade is a testament to the hard work and dedication of our entire team in integrating sustainability into our core business practices. At Walvax, we believe that responsible business practices go hand in hand with innovation in biotechnology. We remain committed to advancing both fronts as we work towards a healthier, more sustainable future. #ESG #SustainableInvesting #Biotechnology #HealthcareInnovation #CorporateResponsibility

Walvax will be exhibiting at CPHI Milan on October 8-10. If you're attending, we'd love to meet you at our booth (16G13). Come say hello and learn about our latest innovations in vaccine R&D and manufacturing! #CPHI2024 #WalvaxAtCPHI #Vaccines #Walvax

Exciting news! Our blockbuster product HPV-2 (Walrinvax™ ) has been pre-qualified by #WorldHealthOrganization . This achievement underscores our commitment to delivering safe, effective and high-quality vaccines to the world, further contributing to WHO's Global Strategy to Accelerate the Elimination of Cervical Cancer #Prequalification #HPV #CervicalCancer

Preserving our planet is a continuous journey. At #Walvax , we're taking steps to minimize our environmental footprint through eco-friendly practices and investments. While proud of our progress, we're driven to do more for a healthier planet. #EarthDay

Here are some highlights from our 2023 Annual Report. We were proud to be among the top 10 manufacturers by value (excluding COVID-19) 2022 in WHO's Global Vaccine Market Report 2023🎉🎉🎉 #WalvaxAnnualReport

At #Walvax , our passion for vaccines brings us together, as our name says it all: We All Love Vaccine X! Walvax produces efficacious, quality, innovative, and affordable products to protect people from the world’s deadliest diseases, and to help everyone live a healthy life!

Recently, our SARS-CoV-2 XBB.1.5 Variant mRNA Vaccine has been approved in China to prevent COVID-19 infection in individuals aged 18+, in line with WHO's recommendation on the use of the monovalent Omicron XBB.1.5 COVID-19 vaccines.

The first dose administered! We've initiated our #PCV13 non-inferiority & co-administration clinical trial with 2P+1 schedule in Indonesia, evaluating the immunogenicity and safety with EPI Vaccines.

Metric
Company Name	Walvax
Symbol
MSH ID	COM:WALVAX:EN
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CN
Stage	Post-IPO Equity
Employee Count
Website	en.walvax.com
LinkedIn	walvax
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.09K
Web Traffic Growth	-0.56
Valuation
Raised Capital	72.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

WALV

COM:WALVAX:EN

Walvax

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue